$28.08
3.51%
NYSE, Oct 01, 04:00 pm EDT. Closed.
ISIN
US03237H1014
Symbol
AMLX

Amylyx Pharmaceuticals Target price 2026 - Analyst rating & recommendation

Amylyx Pharmaceuticals Classifications & Recommendation

Buy
89%
Hold
11%

Amylyx Pharmaceuticals Price Target

Target Price $42.84
Price $28.08
Potential
Number of Estimates 13
13 Analysts have issued a price target Amylyx Pharmaceuticals 2027 . The average Amylyx Pharmaceuticals target price is $42.84. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 18 analysts: 16 Analysts recommend Amylyx Pharmaceuticals to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Amylyx Pharmaceuticals stock has an average upside potential 2027 of . Most analysts recommend the Amylyx Pharmaceuticals stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ -1.53 -1.55
65.46% 1.31%
P/E negative

12 Analysts have issued a Amylyx Pharmaceuticals forecast for earnings per share. The average Amylyx Pharmaceuticals EPS is

$-1.55
unlock
. This is
13.97% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-1.44 5.88%
unlock
, the lowest is
$-1.57 15.44%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-1.53 65.46%
2026
$-1.55 1.31%
unlock
2027
$-1.45 6.45%
unlock
2028
$-0.36 75.17%
unlock
2029
$0.77 313.89%
unlock
2030
$2.10 172.73%
unlock
2031
$2.76 31.43%
unlock
2032
$3.75 35.87%
unlock
2033
$4.09 9.07%
unlock

P/E ratio

Current -21.40 209.46%
2026
-18.81 12.09%
unlock
2027
-20.03 6.49%
unlock
2028
-81.35 306.14%
unlock
2029
37.87 146.55%
unlock
2030
13.83 63.48%
unlock
2031
10.55 23.72%
unlock
2032
7.76 26.45%
unlock
2033
7.11 8.38%
unlock

Current Amylyx Pharmaceuticals Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Guggenheim
Locked
➜
Locked
Locked Aug 27 2026
Guggenheim
Locked
➜
Locked
Locked Aug 19 2026
Baird
Locked
➜
Locked
Locked Aug 19 2026
Mizuho
Locked
➜
Locked
Locked Aug 19 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked Aug 18 2026
Mizuho
Locked
➜
Locked
Locked Aug 17 2026
Citigroup
Locked
➜
Locked
Locked Aug 03 2026
Analyst Rating Date
Locked
Guggenheim:
Locked
➜
Locked
Aug 27 2026
Locked
Guggenheim:
Locked
➜
Locked
Aug 19 2026
Locked
Baird:
Locked
➜
Locked
Aug 19 2026
Locked
Mizuho:
Locked
➜
Locked
Aug 19 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Aug 18 2026
Locked
Mizuho:
Locked
➜
Locked
Aug 17 2026
Locked
Citigroup:
Locked
➜
Locked
Aug 03 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today